x

Search for a networks

* (*) mandatory field

A Phase 3 Open-Label, Multicenter, Randomized Study of ASP2215 Versus Salvage Chemotherapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FLT3 Mutation

  • Type of network : Multinational clinical trials
  • Geographic coverage : Global
  • Funding body(ies) : ASTELLAS PHARMA GLOBAL DEVELOPMENT, INC. 
  • Sponsor : Information not provided
  • Website
  • Coordinator of multinational clinical trial

  • INFORMATION NOT PROVIDED
  • Institution: Information not provided - US
  • ADDRESS: NOT PROVIDED - US
  • UNITED STATES
  • More information
  • Phone  : -
  • Fax  : -
Last update: March 2018

Additional information

The documents contained in this web site are presented for information purposes only. The material is in no way intended to replace professional medical care by a qualified specialist and should not be used as a basis for diagnosis or treatment.